Unicycive Therapeutics, Inc. UNCY

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
27/100
Developing

Ranked against 712 peers in Biotechnology

About Unicycive Therapeutics, Inc.

Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb RZB 012 for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company also … Full UNCY analysis →

Key risks

  • ROIC Below WACC or Peers ROIC at 31.9th percentile suggests inefficient capital deployment.
  • Elevated Debt Risk Debt serviceability is weak (score 0.21), raising refinancing risk.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
32
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where UNCY ranks in Biotechnology

Unicycive Therapeutics, Inc. ranks #550 of 713 scored companies in Biotechnology by moat score — the top 77%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
546 Salarius Pharmaceuticals, Inc. SLRX 27/100 Developing
547 XTL Biopharmaceuticals Ltd. XTLB 27/100 Developing
548 Chimerix, Inc. CMRX 27/100 Developing
549 Larimar Therapeutics, Inc. LRMR 27/100 Developing
550 Unicycive Therapeutics, Inc. UNCY 27/100 Developing
551 ATAI Life Sciences N.V. ATAI 27/100 Developing
552 Addex Therapeutics Ltd ADXN 27/100 Developing
553 Actinium Pharmaceuticals, Inc. ATNM 26/100 Developing
554 Cidara Therapeutics, Inc. CDTX 26/100 Developing

See every Biotech / Pre-Revenue company ranked by moat score →

How UNCY scores on the Corporate Default defenses

Pricing Power

Score 32 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 25 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 27 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 11 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 25 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 64 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding UNCY's moat

What is Unicycive Therapeutics, Inc.'s moat score?

Unicycive Therapeutics, Inc. (UNCY) scores 27 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #550 of 713 scored companies in Biotechnology, the top 77%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Scale & Market Position (64/100) and its weakest is Capital Efficiency (11/100).

How does Unicycive Therapeutics, Inc. compare with other Biotechnology companies?

Unicycive Therapeutics, Inc. ranks #550 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Larimar Therapeutics, Inc. (LRMR) at 27 just above it and ATAI Life Sciences N.V. (ATAI) at 27 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Unicycive Therapeutics, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Unicycive Therapeutics, Inc.?

The Corporate Default template measures 6 defenses, and UNCY scores: Pricing Power (32), Cost Advantage (25), Customer Stickiness (27), Capital Efficiency (11), Resilience (25), Scale & Market Position (64). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000